Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient sur...
KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV) announced today that it intends to offer, subject to market c...
First European launch of EKTERLY expected in Germany Q4 2025EKTERLY now approved in the US, EU, UK and Switzerland with additio...
Needham analyst Serge Belanger reiterates KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and maintains $28 price target.
JMP Securities analyst Jonathan Wolleben maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Market Outperform and raise...
